Evidence mapPaperPMID 40869170Full record

ReviewInternational journal of molecular sciences2025

Neurotransmitter Alterations in Prediabetes and Type 2 Diabetes Mellitus: A Narrative Review.

Roxana-Viorela Ahrițculesei, Lidia Boldeanu, Anda Lorena Dijmărescu, Mohamed-Zakaria Assani, Mihail Virgil Boldeanu, Isabela Siloși, Cristin Constantin Vere

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Special Issue: "Molecular Diagnosis and Treatments of Diabetes Mellitus".International journal of molecular sciences · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roxana-Viorela AhrițculeseiDoctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Lidia BoldeanuDepartment of Microbiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0002-4817-1365
Anda Lorena DijmărescuDepartment of Obstetrics and Gynecology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Mohamed-Zakaria AssaniDoctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0009-0009-3146-8769
Mihail Virgil BoldeanuDepartment of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0003-2481-6138
Isabela SiloșiDepartment of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Cristin Constantin VereDepartment of Gastroenterology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prediabetes and early type 2 diabetes mellitus (T2D) are increasingly recognized as states of both metabolic and neurochemical dysregulation. This narrative review synthesizes emerging evidence of alterations in key neurotransmitter systems-dopamine, serotonin, norepinephrine, gamma-aminobutyric acid, and glutamate-in individuals with prediabetes and diabetes. Beyond peripheral insulin resistance and β-cell dysfunction, disturbances in the central nervous system, especially related to neurotransmitter signaling, may play a role in disease onset and progression. Neuroimaging studies reveal early imbalances in excitatory and inhibitory neurotransmitters, while biochemical and histological findings demonstrate altered receptor expression in both the brain and pancreatic islets. These changes affect metabolic control and are implicated in mood, cognition, and feeding behavior. We investigate the mechanistic links between neurotransmitter dysfunction and glucose metabolism, including the roles of brain insulin resistance, inflammation, mitochondrial stress, and gut-brain axis signaling. Finally, we discuss therapeutic strategies that target neurochemical pathways and highlight the need for longitudinal, sex-aware, and multi-omics studies to refine early interventions. Understanding the neurobiological roots of early T2D could revolutionize risk assessment and open doors for new neuro-metabolic treatments.

Indexed as

Diabetes Mellitus, Type 2Neurotransmitter AgentsPrediabetic StateAnimalsBrainHumansInsulin ResistanceNeurotransmitter Agentsdopaminegamma-aminobutyric acidglutamateneurotransmitternorepinephrineprediabetesserotonintype 2 diabetes mellitus

Identifiers

PMID40869170
PMCPMC12386727

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.